Metrics as of 10/17/2026, 06:14 AM (Berlin time), refresh in progress.
hVIVO Stock
hVIVO plc
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United Kingdom
- CEO
- Yamin Mohammed Khan
- Employees
- 376
- Market cap
- £40 M
- IPO
- 14/12/2012
hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which…
hVIVO stock: price history
1D
-1.7%
1W
-3.3%
1M
-1.7%
6M
-40.8%
YTD
-7.9%
1Y
-19.0%
2Y
-80.3%
5Y
-71.7%
10Y
-75.3%
Next earnings date
Next earnings date
14/04/2027 (in 179 days)
Volatility around earnings
~3% weaker price swings than usual
Ask the agents about hVIVO
hVIVO stock metrics
P/E
-3.22
P/B
1.24
EV/EBITDA
-4.4
RETURN ON EQUITY
-20.1%
NET MARGIN
-39.7%
DEBT/EQUITY
0.43
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.1%
FLOAT SHARES
565,095,841
AVG. DAILY VOLUME (30D)
1,547,633
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about hVIVO stock
What does hVIVO do?
hVIVO plc is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United Kingdom.
The CEO is Yamin Mohammed Khan, the company employs around 376 people.
The IPO was on 14/12/2012; the stock trades on LSE under the ticker HVO.L.
When does hVIVO report next?
The next earnings date is 14/04/2027.
Around past earnings, price swings were roughly -3% stronger than usual.
Does hVIVO pay a dividend?
Yes. The last dividend was £0.20 per share, ex-date 15/05/2025, paid on 11/06/2025.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to hVIVO?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get hVIVO stock analyzed?
Clicking "Analyze stock" lets five strategies assess hVIVO against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.